Global Stocks Estimated To Be Trading Below Fair Value In July 2026

In July 2026, global markets have been marked by volatility, with major indices like the Nasdaq Composite and S&P 500 experiencing declines driven by tech sector losses and geopolitical tensions impacting investor sentiment. Amid these fluctuations, identifying undervalued stocks becomes crucial as they may offer potential opportunities for investors seeking to navigate the complexities of current market conditions.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| VINA TECHLtd (KOSDAQ:A126340) | ₩69000.00 | ₩137891.32 | 50% |
| SHIFT (TSE:3697) | ¥749.60 | ¥1495.04 | 49.9% |
| Samyang Foods (KOSE:A003230) | ₩1120000.00 | ₩2214803.55 | 49.4% |
| Pan-United (SGX:P52) | SGD1.59 | SGD3.16 | 49.7% |
| Matrix Design (SZSE:301365) | CN¥36.80 | CN¥73.26 | 49.8% |
| Info-Tech Systems (SGX:ITS) | SGD0.98 | SGD1.94 | 49.4% |
| Hemnet Group (OM:HEM) | SEK86.00 | SEK171.38 | 49.8% |
| Com.Tel (BIT:CMTL) | €1.87 | €3.70 | 49.4% |
| Casta Diva Group (BIT:CDG) | €3.05 | €6.04 | 49.5% |
| Cambi (OB:CAMBI) | NOK21.70 | NOK42.86 | 49.4% |
We’re going to check out a few of the best picks from our screener tool.
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩14.35 billion.
Operations: The company’s revenue primarily comes from its biotechnology segment, amounting to ₩203.76 million.
Estimated Discount To Fair Value: 23.8%
Alteogen is trading at ₩306,500, which is 23.8% below its estimated fair value of ₩402,093.63 based on future cash flow projections. The company’s revenue and earnings are forecast to grow significantly faster than the Korean market at 47.7% and 44.3% per year, respectively. Recent preclinical data presented at the World ADC Summit highlights Alteogen’s innovative ALT-B4 technology for subcutaneous drug delivery, potentially enhancing systemic exposure and safety profiles over traditional intravenous methods.
Overview: Ningbo Deye Technology Group Co., Ltd. engages in the research, design, development, production, sale, and servicing of solar inverter systems, frequency conversion control systems, environmental electrical appliances, and heat exchangers in China with a market cap of CN¥102.44 billion.
Operations: The company’s revenue segments include solar inverter systems, frequency conversion control systems, environmental electrical appliances, and heat exchangers in China.
Estimated Discount To Fair Value: 30.9%
Ningbo Deye Technology Group is trading at CN¥88.51, 30.9% below its fair value of CN¥128.02 based on discounted cash flow analysis. The company’s revenue and earnings are projected to grow at 26.6% and 26.8% annually, outpacing the Chinese market’s growth rates of 16.1% and 26.1%, respectively, despite an unstable dividend track record. Recent earnings reports show substantial growth in sales and net income compared to the previous year, reinforcing its undervaluation status.
Overview: Furukawa Electric Co., Ltd. operates globally in the fields of Optical Solutions, Digital Infrastructure Components, Energy Infrastructure, Automotive Systems and Metal Solutions, with a market cap of ¥2.48 trillion.
Operations: The company’s revenue segments are Infrastructure at ¥370.86 billion, Functional Products at ¥161.09 billion, Electrical Electronics at ¥765.07 billion, and Service, Development, Etc. at ¥42.21 billion.
Estimated Discount To Fair Value: 10.6%
Furukawa Electric is trading at ¥3,515, slightly below its estimated future cash flow value of ¥3,930.84. The company forecasts significant earnings growth of 21.5% annually over the next three years, surpassing the Japanese market’s average. However, recent financials reveal large one-off items affecting results and debt coverage by operating cash flow remains inadequate. Recent inclusion in major indices like S&P Global 1200 may enhance visibility and investor interest.
Where To Now?
Searching for a Fresh Perspective?
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Ningbo Deye Technology Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com



